BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Hemophilia Alliance - ECPv6.3.7//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://hemoalliance.org
X-WR-CALDESC:Events for Hemophilia Alliance
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240507T140000
DTEND;TZID=America/New_York:20240507T150000
DTSTAMP:20260515T184738
CREATED:20240311T173328Z
LAST-MODIFIED:20240311T173328Z
UID:46401-1715090400-1715094000@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A webinar from Genentech - Reinforcing 10+ years of clinical trial experience with a subcutaneous prophylaxis treatment
DESCRIPTION:Date: Tuesday\, May 7\, 2024\nTime: 2:00pm – 3:00pm ET \n\n \nTITLE:\nReinforcing 10+ years of clinical trial experience with a subcutaneous prophylaxis treatment\, including the latest data in infants \nWEBINAR OBJECTIVE:\nDr. Mike Silvey will share his perspective on managing patients with hemophilia A using a subcutaneous prophylactic treatment. The presentation will include the pivotal efficacy and safety data that is the foundation of the ongoing clinical trial program in patients with and without FVIII inhibitors\, including an overview of real-world experience. Dr. Silvey will share updates from the latest trial in infants and previously untreated patients. The webinar will feature brain teasers\, and showcase social media that’s engaging the hemophilia community and polls. Q&A session will follow the program.  \nSPEAKER:\n\nMichael Silvey\, DO\nHTC Director – Children’s Mercy HTC\, Kansas City\, MO.\nAssociate Professor of Pediatrics – University of Missouri-Kansas City School of Medicine. \nSPEAKER’S BIO:\nMichael Silvey\, DO\, is an Associate Professor of Pediatrics at the University of Missouri-Kansas City School of Medicine and the Associate Director of the Kansas City Regional Hemophilia Treatment Center at Children’s Mercy Hospital in Kansas City\, Missouri. He received his medical degree from The Chicago College of Osteopathic Medicine. He completed his general pediatrics residency at the University of Texas Health Science Center-San Antonio and his pediatric hematology/oncology fellowship at Children’s Mercy Hospital in Kansas City\, Missouri. His primary clinical and research interests are hemophilia\, inherited platelet function disorders\, and the coagulation system in patients with congenital heart disease as well as patients need ECMO. Dr. Silvey serves as a primary investigator for several research studies involving both bleeding and clotting disorders. In addition to enjoying taking care of pediatric bleeding disorder patients\, he also likes to spend lots of time with his wife and two children and getting out on the golf course.
URL:https://hemoalliance.org/alliance-events/a-webinar-from-genentech-reinforcing-10-years-of-clinical-trial-experience-with-a-subcutaneous-prophylaxis-treatment/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240514T140000
DTEND;TZID=America/New_York:20240514T150000
DTSTAMP:20260515T184738
CREATED:20240410T142934Z
LAST-MODIFIED:20240410T142934Z
UID:46542-1715695200-1715698800@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Presents - Hemophilia Alliance Network Services/Emerging Therapy Solutions
DESCRIPTION:Date: Tuesday\, May 14\, 2024\nTime: 2:00pm – 3:00pm ET \n\n \nTITLE:\nHemophilia Alliance Network Services/Emerging Therapy Solutions \nA Gene Therapy Payer Contract \nWEBINAR DESCRIPTION:\nThe past twelve to eighteen months have been landmark times for gene therapy treatments for individuals with bleeding disorders.  While the third party payers\, reinsurers and prescription benefit plans have begun forming strategies for benefit plan coverage\, pricing\, patient qualifications and follow up reporting. Hemophilia Alliance Network Services (HANS) has been hard at work arranging for adequate contractual arrangements with important entities influencing Payor behavior and strategies for the use of Gene Therapy.  The HANS goal was to create relationships with entities that could offer acceptable contractual terms but importantly influence the common prior authorization process to provide a clear path for delivery of the product\, provision of the service to Hemophilia Treatment Center (HTC) patients\, and subsequent confidence in the payment for this high-cost therapy.   \nHANS is pleased to announce that it has executed an Agreement with Emerging Therapy Solutions (ETS) effective January 1\, 2024.  Emerging Therapy Solutions® (ETS)\, an industry leader in providing cutting-edge services to help payers and other risk-bearing entities prepare for the accelerating growth in cell and gene therapies and other high-cost\, complex treatments. This webinar will provide a high-level overview from HANS leadership regarding the Agreement with ETS as well as how HTCs can gain access to this Agreement.  HANS will ask the leadership from ETS to describe the business model and services they provide\, the ETS customer base and provide important information on how to HTCs can intersect with ETS to obtain necessary approvals for gene therapy treatments for qualified patients.  During this one-hour webinar you will hear important details on the authorization process\, clinical review and administrative details that provide a clearer path to benefit coverage and payment for HTC patients rather than the time-consuming process of single case agreements with payors that many HTCs have experienced thus far. \nThis webinar is available to ALL Hemophilia Treatment Centers that are members of the Hemophilia Alliance\, it is NOT restricted to participating members of the Hemophilia Alliance Network Services Agreements.  If an HTC is not a HANS member today and wishes to join HANS to access the ETS agreement \, please reach out to your Member and Community Relations Team Member who will assist you.  Administrators\, Finance team members\, Pharmacists and Physicians are ideal candidates to attend this webinar.  However\, it is open to any interested employee of member HTCs. \nSPEAKERS & BIOs:\n\nRoland Lamy\, Jr. – Vice President of Payer Relations\nRoland Lamy has held a variety of leadership positions in the healthcare industry including sales management\, underwriting\, employee benefit and rate development\, hospital and physician negotiations and contracting\, and government programs oversight and business management. Click here to learn more about Roland… \n\nZack Duffy – Director of Member & Community Relations\nMost recently\, Zack Duffy was the Program Administrator for The Hemophilia Center at Oregon Health & Science University (OHSU) overseeing the administrative and business functions of the clinic and pharmacy. He started with the Factor Program at The Hemophilia Center in 2013\, when it was a 340B physician dispense model. In 2017\, he led the transition from a physician dispense to a pharmacy dispensing model. Click here to learn more about Zack…
URL:https://hemoalliance.org/alliance-events/hemophilia-alliance-presents-hemophilia-alliance-network-services-emerging-therapy-solutions/
CATEGORIES:Members Only,Webinar
END:VEVENT
END:VCALENDAR